SVA — SINOVAC BIOTECH LTD
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1084201 ·
China
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
2026-08-17
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 8,541,725,000 | 488,248,000 | 2,145,473,000 |
| Jun 2025 | — | — | — | — | 11,987,067,000 | 182,626,000 | 5,643,587,000 |
| Dec 2024 | — | — | — | — | 12,337,281,000 | 335,273,000 | 2,043,851,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$2,815,942,000
Inventory
$94,309,000
Receivables
$313,087,000
ST Investments
$5,483,073,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 386,013,000 | -287,287,000 | -59,680,000 | 8,541,725,000 | 2,145,473,000 | — | -512,184,000 |
| Dec 2024 | 361,374,000 | -475,256,000 | 90,905,000 | 12,337,281,000 | 2,043,851,000 | — | -56,891,000 |
| Dec 2023 | 470,170,000 | -605,261,000 | -13,491,000 | 13,657,974,000 | 1,635,207,000 | — | 138,645,000 |
| Dec 2022 | 1,492,761,000 | -460,854,000 | 113,866,000 | 14,114,568,000 | 1,401,907,000 | — | -770,745,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.11T | $1246.93 | — |
| JNJ | JOHNSON & JOHNSON | $658.00B | $273.04 | — |
| ABBV | AbbVie Inc. | $467.44B | $264.52 | — |
| MRK | Merck & Co., Inc. | $371.70B | $150.66 | — |
| NVSEF | NOVARTIS AG | $310.96B | $163.60 | — |
News headlines (Yahoo Finance, 1h cache)
SINOVAC Reports Unaudited First Half of 2026 Financial Results
2026-08-17 12:00 · Yahoo
SINOVAC Regained Compliance With the Nasdaq Global Market’s Listing Requirements
2026-06-15 10:00 · Yahoo
SINOVAC Reports Unaudited and Unreviewed Second Half of 2025 Financial Results and Files 2025 Annual Report on Form 20-F
2026-06-05 20:01 · Yahoo
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report
2026-05-29 20:01 · Yahoo
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend
2026-07-15 06:00 · Yahoo
OrbiMed Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing
2026-02-20 05:22 · Yahoo
Coxsackievirus Infections Market Research Report 2025-2035: High Burden of Pediatric and Neonatal Infections, Link to Type 1 Diabetes Risk, Advances in Vaccine Development Driving Expansion
2026-02-06 10:17 · Yahoo
Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment
2025-11-11 22:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.